Third-Party Payers and the Costs of Biomedical Research
Iltis, Ana S.
Kennedy Institute of Ethics Journal 2005 June; 15(2): 135-160
Four principal arguments have been offered in support of requiring public and private third-party payers to help fund medical research: (1) many of the costs associated with clinical trial participation are for routine care that would be reimbursed if delivered outside of a trial; (2) there is a need to promote scientific research and medical progress and lack of coverage is an impediment to enrollment; (3) to cover the costs of trials expands health care and treatment options for the sick; and (4) it is beneficial for private insurers to cover the costs associated with cancer clinical trials because doing so makes such companies more attractive to consumers. Although many see third-party-payer coverage as a victory for patients and for the future of research, requiring coverage of services provided in a trial beyond those that would be provided to a comparable patient outside the research context raises a number of concerns.
Showing items related by title, author, creator and subject.
Holleman, Warren L.; Edwards, David C.; Matson, Christine C. (1994)
Chalmers, Thomas C.; van den Noort, Stanley; Lockshin, Michael D.; Waksman, Byron H. (1983-11-24)The Arthritis Foundation and the National Multiple Sclerosis Society sponsored a July 1983 workshop to explore methods of payment for clinical trials of expensive new therapies for the treatment of chronic disease. ...
Liver Transplant Candidate Stratification Systems Implications for Third-Party Payers and Organ Allocation Muto, Paul; Freeman, Richard B.; Haug, Craig E.; Lu, Amy; Rohrer, Richard J. (1994-01)